Drug news

Medtronic launches Powerease System for Spine Surgery

Read time: 1 mins

Last updated:15th Apr 2012

Published:15th Apr 2012

Source: Pharmawand

Medtronic, has announced launched the Powerease System, an innovative system of electronic instruments designed specifically for use in instrumented or reconstructive spine surgery. This system brings new capability to the operating room through compatibility with two of the leading pedicle screw platforms on the market, the CD Horizon Solera Spinal System and the TSRH 3Dx Spinal System, and is integrated with other advanced surgical technologies, specifically Medtronic's Nim-Eclipse neuromonitoring, Q-Arm imaging, and Stealth Station navigation systems.The Powerease System reduces surgeon's fatigue associated with repetitive hand motion and enhances surgeon control, including in complex reconstructions of the spine.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

The FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia below-the-knee

Abbott announced that the FDA has approved the Esprit BTK Everolimus Eluting Resorbable Scaffold System (Esprit BTK System), a breakthrough innovation for people with chronic limb-threatening ischemia (CLTI) below-the-knee (BTK)

2 mins

Drug news

Promising findings in phase IIb/III clinical trial of NRX 101 vs. lurasidone for treatment of suicidal bipolar depression

NRx Pharmaceuticals, Inc. announced that its Breakthrough Therapy designated investigational drug NRX 101 vs lurasidone demonstrated a promising, though not yet statistically significant 33% reduction in suicidality together with a 70% reduction (P=.076) reduction in symptoms of akathisia – a side effect of antidepressants that is closely linked to suicide and considered a medical emergency

1 min

Drug news

FDA approval of Ingrezza Sprinkle (valbenazine) capsules for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease

Neurocrine Biosciences, Inc. announced the FDA has approved Ingrezza Sprinkle (valbenazine) capsules, a new oral granules formulation of Ingrezza (valbenazine) capsules prescribed for the treatment of adults with tardive dyskinesia and chorea associated with Huntington's disease

1 min

See all news